
The European Medicines Agency’s (EMA) expert committee, the CHMP, has given a positive opinion for 13 news drugs, following the committee’s February monthly meeting. This brings the year’s total up to 20 new drugs pending official approval, while 17 existing drugs can await indication expansions.
The Committee for Medicinal Products for Human Use has first given a positive opinion to Immunocore Ireland’s drug Kimmtrak (tebentafusp), a treatment for the rare eye cancer type known as uveal melanoma. This is a difficult to treat condition, as it spreads quickly and has proven resistent to existing treatments, and the drug was therefore reviewed under the CHMP’s accelerated assessment program.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app